RPS6KA1 and melanoma: In conclusion, RSK inhibitors may represent a novel therapeutic tool for malignant melanomas benefiting from their general usefulness in melanomas with dysregulated MAPK signaling, a tolerable toxicity profile as well as from their anti-tumor efficacy on two levels: first, a direct effect on proliferation and survival; and second, an enhanced immunogenicity of the tumor cells.